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Alternatively spliced tissue factor levels are elevated
in the plasma of patients with chronic liver diseases
Nathalie I. Caversaccioa,b,d, Maria D. Reina Caroa,d, Raja Princea,d, Martin Müllerc,e, Clayton S. Lewisf,
Vladimir Y. Bogdanovf, Jean-François Dufourb,d,* and Anne Angelillo-Scherrera,d,*
Objectives In patients with chronic liver diseases, hypercoagulability can contribute to the progression of ﬁbrosis and
complications of cirrhosis. Tissue factor (TF) is a transmembrane glycoprotein that initiates the extrinsic pathway of blood
coagulation. Recent investigations have established that TF is elevated in patients with pancreatic cancer, blood disorders,
diabetes, and cardiovascular disease. Alternatively spliced tissue factor (asTF), a secreted form of TF, induces angiogenesis and
exhibits low-level procoagulant activity. The aim of this study was to investigate whether the circulating levels of asTF are elevated
in the plasma of patients with liver disease.
Materials and methods In a single-center study, we retrospectively analyzed asTF plasma levels in healthy participants and
patients having stage F0–F3 liver ﬁbrosis, liver cirrhosis, as well as hepatocellular carcinoma (HCC). AsTF plasma levels were
measured using a sandwich enzyme-linked immunosorbent assay. Values were expressed as median with interquartile
range (IQR).
Results The lowest median plasma asTF concentration (94 pg/ml, IQR: 33–275) was found in the healthy control group. The
patients with low-grade liver ﬁbrosis (F0–F1 group) displayed the highest median asTF concentration (404 pg/ml, IQR: 277–789).
Signiﬁcant differences between the asTF levels in the plasma of healthy participants and those in patients with grade F0–F1
ﬁbrosis (P< 0.001), patients with grade F2–F3 ﬁbrosis (P= 0.019), patients with cirrhosis (P=0.004), and patients with HCC
(P<0.001) were found using a Wilcoxon rank-sum test. Treatment-naive patients with HCC had signiﬁcantly higher asTF levels
(P=0.018) than those receiving treatment. AsTF levels were found to increase with worsening Child–Pugh scores and
heightened liver disease activity.
Conclusion AsTF levels are elevated in patients with chronic liver diseases, which increase with worsening Child–Pugh scores
and decrease following HCC therapy. Eur J Gastroenterol Hepatol 00:000–000
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
The coagulation system participates in the progression of
liver diseases. It has been recently recognized that the
formation of microthrombi in the hepatic sinusoids and
elevated plasma levels of von Willebrand factor are asso-
ciated with more advanced liver disease [1–3]. The lack of
von Willebrand factor reduces the progression of liver
ﬁbrosis in mice through a reduction in collagen deposition
[3]. Low levels of factor VII activating protease are asso-
ciated with enhanced liver ﬁbrosis in humans [4].
However, many aspects of the role of coagulation factors
in hepatic pathophysiology remain to be investigated.
Tissue factor (TF) is a transmembrane glycoprotein that
initiates the extrinsic pathway of blood coagulation by
acting as a cellular receptor and cofactor for factor VII. TF
is expressed in monocytes, ﬁbroblasts, smooth muscle
cells, cerebral cortex, renal glomeruli, cardiac myocytes,
spleen trabeculae and capsule, gut mucosa, epidermis,
bronchial mucosa, alveolar epithelial cells, and Schwann
cells [5,6]. Hepatocytes also express TF but at low con-
centrations [5].
Circulating TF (‘blood-borne’ or TF in cell-free plasma)
exists in two forms: full-length tissue factor (ﬂTF), encoded by
6 exons, and alternatively spliced tissue factor (asTF), with a
deletion of exon 5 owing to alternative splicing of exon
4 directly to exon 6; this leads to a frame shift in exon
6, yielding a transmembrane domain-lacking isoform that can
be secreted [7,8]. Regulation of TF pre-mRNA splicing was
shown to depend on SR proteins in monocytes and endo-
thelial cells [9,10]. Additionally, it has been reported that TF
gene expression is regulated by nuclear factor-κB [11].
Recent investigations have established that total circu-
lating TF is elevated in patients with diverse conditions
such as diabetes mellitus, myocardial infarction, unstable
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angina pectoris, sickle-cell disease, antiphospholipid anti-
body syndrome and pancreatic cancer [12–16]. These
patients are at risk of developing thrombosis owing to
higher activity of circulating TF [12,16]. In patients with
cirrhosis, TF expression is increased in endothelial cells of
splenic vein induced by interleukin-17A, an inﬂammatory
cytokine which is elevated in liver cirrhosis [17]. Rautou
et al. [18] have shown that hepatocyte TF contributes to
the activation of coagulation in chronic liver disease.
AsTF induces angiogenesis by acting as an integrin
ligand and can also promote coagulation in association
with phospholipid surfaces [7,19]. AsTF has been reported
to act on cancer cells by β1 integrins and to induce cell
proliferation, which contributes to breast and pancreatic
ductal carcinoma growth [20,21]. Patients with pancreatic
cancer have signiﬁcantly higher plasma asTF concentra-
tions than healthy participants, and high asTF levels in
circulation are signiﬁcantly associated with a lower like-
lihood of tumor resectability [22]. As recently published,
targeting asTF can impede tumor growth in an orthotopic
murine model of pancreatic ductal adenocarcinoma [23].
The aim of this study was to investigate whether the
circulating levels of asTF are elevated in the plasma of
patients with liver ﬁbrosis, cirrhosis, and hepatocellular
carcinoma (HCC).
Materials and methods
Study design
This observational, single-center study retrospectively ana-
lyzed data from patients with liver disease and healthy blood
donors. Patients’ plasma samples were collected between
2011 and 2017 at the Department of Visceral Surgery and
Medicine, Bern University Hospital, Switzerland. Healthy
participants’ plasma samples were collected between January
and March 2017 by voluntary blood donations. All patients
and healthy volunteers signed an informed consent allowing
use of plasma samples for research. The study was conducted
with the approval of the Kantonale Ethikkommission Bern
(Basec-Nr. 2016-00213).
Data collection
Patients had liver disease owing to hepatitis B virus (HBV)
and hepatitis C virus (HCV), alcoholic steatohepatitis (ASH),
nonalcoholic steatohepatitis (NASH), hereditary hemochro-
matosis, α-1-antitrypsin deﬁciency and cryptogenic liver dis-
ease. Transient elastography (TE) cutoffs have been used
according to etiologies for staging liver ﬁbrosis (EASL-ALEH
Clinical Practice Guidelines) [24]. The determination of
TE for the measurement of liver stiffness occurred no more
than one month from the time point of plasma acquisition.
Nonadvanced ﬁbrosis (ﬁbrosis stage 0–1) was deﬁned on a
cutoff of less than 6.0 kPa in HBV, less than 5.2 kPa in HCV,
less than 7.0 kPa in ASH/NASH, and less than 7.9 kPa in
hereditary hemochromatosis, α-1-antitrypsin deﬁciency, and
cryptogenic liver disease. Fibrosis stage 2–3 was deﬁned on a
cutoff of 6.0–10.9 kPa in HBV, 5.2–12.8 kPa in HCV,
7.0–10.2 kPa in ASH/NASH, and 7.9–11.8 kPa in hereditary
hemochromatosis, α-1-antitrypsin deﬁciency, and crypto-
genic liver disease.
For the diagnosis of cirrhosis (ﬁbrosis stage 4), cutoff of
11.0 kPa in HBV, 12.9 kPa in HCV, 10.3 kPa in ASH/
NASH, and 11.9 kPa in hereditary hemochromatosis, α-
1-antitrypsin deﬁciency, and cryptogenic liver disease were
used [24].
The HCC group comprised patients with tumors who
had been diagnosed based on typical radiological criteria
using computed tomography or MRI with contrast
enhancement.
The control group comprised blood donors matched by
sex and age. These participants were healthy because the
Swiss Red Cross had deemed them eligible as blood donors
after their usual checkup procedure, which includes
screening for a number of organ dysfunctions, notably
liver diseases. Plasma samples were provided by the
Interregional Blood Transfusion Service of the Swiss Red
Cross, Bern, Switzerland.
Enzyme-linked immunosorbent assay
The obtained samples were stored at −80°C and gently
thawed before testing. AsTF-speciﬁc sandwich enzyme-
linked immunosorbent assay was used to evaluate as TF
protein levels in plasma samples [25]. In brief, plasma
samples were added to microplate wells precoated with a
capture antibody. A washing step was then performed to
remove the unbound material. Afterwards, peroxidase-
conjugated monoclonal antibody speciﬁc for human asTF
was added to the wells. To remove the excess of anti-asTF
antibody-peroxidase conjugate, another washing step was
carried out. The action of the bound peroxidase was
revealed by its reaction with tetramethylbenzidine. The
reaction was stopped by sulfuric acid (H2SO4), and the
absorbance at 450 nm was immediately measured. The color
intensity was directly proportional to the amount of asTF in
the sample, derived using asTF protein standard curve. For
the batch of prototype enzyme-linked immunosorbent assay
sets used in this study (10 96-well kits), a consistently reli-
able sensitivity cutoff across the entire study was 500 pg/ml
(Supplementary Table S1, Supplemental digital content 1,
http://links.lww.com/EJGH/A330).
Statistical analysis
Stata 13.1 (StataCorp, College Station, Texas, USA) was
used to perform the statistical analysis. Visually and sta-
tistically (Shapiro–Wilk test), asTF levels as well as their
log-transformation were not normally distributed. Thus,
asTF levels were reported as median with interquartile
range (IQR), and nonparametric tests were used for group
comparisons. The Kruskal–Wallis test with the Wilcoxon
rank-sum test as a post-hoc test was performed to compare
the distribution of continuous variables between the
groups. The Spearman’s correlation coefﬁcient was calcu-
lated to test for a linear association between asTF values
and different variables. P values less than 0.05 were con-
sidered statistically signiﬁcant.
Results
AsTF levels were measured in the plasma of 60 healthy
participants, 48 patients having stage 0–1 liver ﬁbrosis
(F0–F1 group), 33 patients with stage 2–3 liver ﬁbrosis
(F2–F3 group), 65 patients with liver cirrhosis (cirrhotic
group), and 128 patients with HCC. The patients’ major
characteristics are shown in Table 1.
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The most common etiology of liver disease was ASH
and NASH. The second largest group comprised patients
with chronic viral infection, that is, hepatitis B and hepa-
titis C. A total of 37 patients with cryptogenic liver disease,
hereditary hemochromatosis, and α-1-antitrypsin deﬁ-
ciency were categorized into the mixed etiology group.
The median asTF concentrations for each patient group
are shown in Table 2. The lowest median plasma asTF
concentration (94 pg/ml, IQR: 33–275) was detected in the
healthy control group. The patients with low-grade liver
ﬁbrosis (F0–F1 group) displayed the highest median asTF
concentration (404 pg/ml, IQR: 277–789), followed by
patients with HCC (392 pg/ml, IQR: 232–812). Median
plasma asTF for patients with an advanced liver ﬁbrosis
(F2–F3 group) was 356 (IQR: 44–859) pg/ml. In patients
with cirrhosis, median plasma asTF was 228 (IQR:
108–442) pg/ml. Correlation analysis is shown in Table 3.
Plasma asTF concentrations in healthy participants
(94 pg/ml, IQR: 33–275) were signiﬁcantly lower com-
pared with all patients with chronic liver disease (373 pg/
ml, IQR: 191–721) (Fig. 1).
Healthy participants were found to have signiﬁcantly
less circulating asTF than patients with grade F0–F1
ﬁbrosis, grade F2–F3 ﬁbrosis, cirrhosis, and HCC.
Additionally, both patients with grade F0–F1 ﬁbrosis and
those with HCC were found to have signiﬁcantly higher
circulating asTF than patients with cirrhosis as determined
by a Wilcoxon rank-sum test (Fig. 2).
There were no effects of sex, age and underlying liver
disease (HBV, HCV, ASH/NASH, and other liver disease)
on asTF levels (Table 3 and Supplementary Table S2,
Supplemental digital content 1, http://links.lww.com/
EJGH/A330).
There was no correlation detectable between the grade
of liver ﬁbrosis (measured by TE) and asTF levels in
patients with grade 0–4 ﬁbrosis (r=− 0.204, P=0.027)
(Fig. 3) nor was there a correlation in untreated patients
between the levels of circulating asTF and the size of HCC
tumors measured radiologically (r=0.030, P=0.865)
(data not shown).
AsTF levels were not signiﬁcantly affected by either
HBV undertreatment (P=0.398) or eradicated HCV
(P= 0.076) or by active alcohol consumption (P=0.069)
in patients with ASH (data not shown). However, patients
with HCC who beneﬁted from therapy such as liver
transplantation, curative resection, trans-arterial che-
moembolization, radiofrequency ablation, selective inter-
nal radiation therapy, and systemic therapy with sorafenib
displayed signiﬁcantly lower plasma asTF concentrations
than treatment-naive patients (Fig. 4). Additionally, asTF
levels rose with increased disease severity in patients with
cirrhosis, with patients scored as Child–Pugh C having
higher levels than those scored as Child–Pugh A (Fig. 5).
Although a similar trend in circulating asTF was observed
when patients with HCC were stratiﬁed based on their
Child–Pugh scores, this did not reach signiﬁcance.
However, when all patients receiving Child–Pugh scores
were analyzed together, that is, those with cirrhosis and/or
HCC, it was found that patients with Child–Pugh C score
had signiﬁcantly higher circulating asTF than those with
either Child–Pugh B (P=0.036) or Child–Pugh A
(P= 0.009) score.
Finally, we compared patients with untreated HBV and
HCV, active alcohol consumption, and active NASH with
alanine aminotransferase (ALT) more than 50 U/I (active
liver disease, n= 40) versus patients with untreated HBV
and HCV, active alcohol consumption, and active NASH
Table 1. Demographics and clinical characteristics of healthy participants and patients with F0–F3 ﬁbrosis, cirrhosis, and hepatocellular carcinoma
Healthy participants
(n=60)
Patients with grade 0–1
ﬁbrosis (n=48)
Patients with grade 2–3
ﬁbrosis (n=33)
Patients with cirrhosis
(n=65)
Patients with HCC
(n=128)
Age [median (IQR)] (years) 58 (57–60) 53 (45–61) 56 (42–60) 58 (50–62) 66 (59–74)
Sex [n (%)]
Male 35 (58.3) 28 (58.3) 23 (69.7) 46 (70.8) 111 (86.7)
Female 25 (41.7) 20 (41.7) 10 (30.3) 19 (29.2) 17 (13.3)
Etiology [n (%)]
HBV 0 (0.0) 1 (2.1) 6 (18.2) 1 (1.5) 10 (7.8)
Undertreatment 0 (0.0) 0 (0.0) 2 (33.3) 0 (0.0) 8 (80.0)
HCV 0 (0.0) 13 (27.1) 16 (48.5) 11 (16.9) 38 (29.7)
Eradicated 0 (0.0) 2 (15.4) 7 (43.8) 0 (0.0) 20 (52.6)
ASH 0 (0.0) 5 (10.4) 6 (18.2) 34 (52.3) 42 (32.8)
Active alcohol consumption 0 (0.0) 4 (12.9) 5 (45.5) 12 (27.9) 14 (25.0)
NASH 0 (0.0) 26 (54.2) 5 (15.1) 9 (13.9) 14 (10.9)
Mixed liver disease 0 (0.0) 3 (6.2) 0 (0.0) 10 (15.4) 24 (18.8)
HCC treatment [n (%)] – – – – 83 (64.8)
Active liver disease (ALT>50 U/l)
[n (%)]
– 20 (45.5) 9 (27.3) 11 (16.9) –
AST [median (IQR)] (U/l) – 36 (26–47) 35 (27–54) 54 (33–78) 62 (39–104)
ALT [median (IQR)] (U/l) – 53 (30–75) 37 (24–83) 34 (20–57) 38 (29–86)
AFP [median (IQR)] (kU/l) – – – – 11 (5–110)
Fibroscan [median (IQR)] (kPa) – 5.0 (4.0–6.1) 7.5 (6.4–7.9) 20.9 (16–34.8) –
Child–Pugh score [n (%)]
A 0 (0.0) 0 (0.0) 0 (0.0) 22 (41.5) 83 (64.8)
B 0 (0.0) 0 (0.0) 0 (0.0) 27 (50.9) 31 (24.2)
C 0 (0.0) 0 (0.0) 0 (0.0) 4 (7.6) 4 (3.1)
MELD-score (6–40) [median (IQR)] – – – 11 (9–13) 8 (7–11)
Tumor size in untreated patients
[median (IQR)] (cm2)
– – – – 31.3 (8.8–79.5)
AFP, α-fetoprotein; ALT, alanine aminotransferase; ASH, alcoholic steatohepatitis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IQR,
interquartile range; MELD, model for end-stage liver disease; NASH, nonalcoholic steatohepatitis.
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with ALT up to 50 U/I (no active liver disease, n=44). As a
cutoff to deﬁne the activity of liver disease, we used ALT
more than 50 U/l. Patients with active liver disease showed
signiﬁcantly higher asTF levels (583 pg/ml, IQR:
221–1088) than patients with no active liver disease
(371 pg/ml, IQR: 59–661) (Fig. 6).
Discussion
This is the ﬁrst study that investigates the circulating levels of
asTF in patients with liver ﬁbrosis, cirrhosis, and HCC. Our
data revealed that the asTF levels were elevated not only in
patients with HCC but also in patients with cirrhosis and
even in some patients with and without ﬁbrosis.
Interestingly, patients with no ﬁbrosis or minimal ﬁbrosis
(F0–F1 group) showed signiﬁcantly higher asTF levels than
patients with cirrhosis. Because asTF expression levels
usually follow ﬂTF expression levels, this may be caused by
an increased TF-dependent coagulation activity in a low-
grade ﬁbrotic liver compared with a cirrhotic liver [26,27].
Thus, we propose that coagulation activation may occur
early in the progress of liver disease and independently of
ﬁbrosis. Liver parenchymal cells synthesize most coagulation
factors; however, in the case of hepatic insufﬁciency, their
production is impaired. This leads to alterations in blood
coagulation, with disruptions in the balance between pro-
coagulation and anticoagulation factors [26].
An earlier study showed that asTF levels were positively
associated with an increased thrombotic tendency in
chronic hemodialysis patients [28]. The lack of a correla-
tion between grade of liver ﬁbrosis and plasma asTF levels
may be owing to a contribution to the formation of
microthrombi in hepatic sinusoids promoting liver disease
progression rather than a direct involvement of asTF in the
Table 2. Plasma alternatively spliced tissue factor levels (pg/ml) in healthy participants and patients with ﬁbrosis, cirrhosis, and hepatocellular
carcinoma
Healthy participants
(n=60)
Patients with grade 0–1
ﬁbrosis (n=48)
Patients with grade 2–3
ﬁbrosis (n=33)
Patients with cirrhosis
(n=65)
Patients with HCC
(n=128)
asTF [median (IQR)] (pg/ml)
Males (n=243) 82 (6–336) 583 (303–981) 270 (9–859) 213 (108–409) 410 (233–908)
Females (n=91) 135 (41–242) 349 (222–421) 515 (275–1781) 249 (104–468) 364 (170–559)
Total (n=332) 94 (33–275) 404 (277–789) 356 (44–859) 228 (108–442) 392 (232–812)
asTF, alternatively spliced tissue factor; HCC, hepatocellular carcinoma; IQR, interquartile range.
Table 3. Correlation analysis (Spearman’s rank correlation coefﬁcient) between plasma alternatively spliced tissue factor levels (pg/ml) and different
clinical parameters
asTF and … Spearman’s ρ P-value
Age (patients with F0–F3 ﬁbrosis, patients with cirrhosis and patients with HCC) (n=274) 0.032 0.599
Sex (patients with F0–F3 ﬁbrosis, patients with cirrhosis, and patients with HCC) (n=274) 0.051 0.398
AFP (patients with cirrhosis and patients with HCC) (n=193) 0.171 0.023
AST (patients with F0–F3 ﬁbrosis, patients with cirrhosis and patients with HCC) (n=233) 0.175 0.008
ALT (patients with F0–F3 ﬁbrosis, patients with cirrhosis, and patients with HCC) (n=232) 0.216 0.001
MELD-score (patients with cirrhosis and patients with HCC) (n=181) −0.172 0.818
Tumor size (untreated patients with HCC) (n=36) 0.030 0.865
AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease.
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Fig. 1. Comparison of the distribution of plasma alternatively spliced tissue
factor (asTF) levels in healthy participants (n= 60) and patients with chronic
liver disease (n=274). Thick bars indicate median asTF concentrations, and
thin bars the interquartile range. For illustration purposes, asTF values more
than 2000 pg/ml are shown as 2000 pg/ml.
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Fig. 2. Comparison of the distribution of plasma alternatively spliced tissue
factor (asTF) levels in patients with ﬁbrosis, patients with cirrhosis, and patients
with hepatocellular carcinoma (HCC). Healthy participants (n=60), patients with
ﬁbrosis 0–1 (n=48), patients with ﬁbrosis II–III (n=33), patients with cirrhosis
(n=65), and patients with HCC (n=128). Thick bars indicate median asTF
concentrations, and thin bars the interquartile range. For illustration purposes,
asTF values more than 2000 pg/ml are shown as 2000 pg/ml.
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ﬁbrogenic process. Interestingly, it has been reported that
the amount of TF was higher in patients with HIV, HCV,
and HIV/HCV coinfection with advanced ﬁbrosis than
those with low ﬁbrosis [29]. Indeed, Villa et al. [30]
reported previously that an anticoagulant treatment with
enoxaparin, which acts on microthrombosis, improves
liver function and Child–Pugh score, thus decreasing the
progression of liver disease.
In the context of this study, three important ﬁndings
were revealed. First, treatment-naive patients with HCC
had signiﬁcantly higher asTF levels than those receiving
treatment, indicating that liver cancer burden may favor
production of circulating asTF. Second, patients with
Child–Pugh A score had signiﬁcantly lower asTF levels
than those with Child–Pugh C score. Our data are in line
with those reported by Rautou et al. [31] demonstrating
that microparticle TF activity increases with cirrhosis
severity as assessed by Child–Pugh score.
Third, patients with active liver disease had signiﬁcantly
higher circulating asTF levels than patients with no active
liver disease. Therefore, we propose that the activity of
liver disease affects the level of asTF in plasma. This could
explain why F0–F1 patients (20 patients with active liver
disease, 45.5%) displayed higher asTF levels than patients
with liver cirrhosis (11 patients with active liver disease,
16.9%).
Regarding the different liver cell types, hepatocytes
express low levels of TF [5]. In mice, liver injury induces
coagulation through upregulation of hepatocyte TF [32].
Kupffer cells and endothelial cells are able to express TF
[33,34]. One interesting question that remains to be
answered is whether there is an expression of ﬂTF/asTF in
hepatic stellate cells and if so, whether the expression levels
differ in ﬁbrosis compared with cirrhosis.
Our study has several limitations. It is a single-center
study with a retrospective design. Furthermore, the sample
sizes of some subgroups were small, so the study might not
have had sufﬁcient power to reveal statistically signiﬁcant
differences and/or associations.
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Fig. 3. Spearman’s rank correlation analysis of circulating alternatively
spliced tissue factor (asTF) levels and transient elastography in patients with
grade 0–4 ﬁbrosis (n= 146). For illustration purposes, asTF values more than
2000 pg/ml are shown as 2000 pg/ml.
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Fig. 4. Comparison of the distribution of plasma alternatively spliced tissue
factor (asTF) levels in untreated patients with hepatocellular carcinoma (HCC)
(n=45) and treated patients with HCC (n= 83). Thick bars indicate median
asTF concentrations, and thin bars the interquartile range. For illustration
purposes, asTF values more than 2000 pg/ml are shown as 2000 pg/ml.
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Fig. 5. Comparison of the distribution of plasma alternatively spliced tissue
factor (asTF) levels in patients with cirrhosis with Child–Pugh A (n=22),
Child–Pugh B (n=27) and Child–Pugh C (n= 4). Thick bars indicate median
asTF concentrations, and thin bars the interquartile range. For illustration
purposes, asTF values more than 2000 pg/ml are shown as 2000 pg/ml.
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Fig. 6. Comparison of the distribution of plasma alternatively spliced tissue
factor (asTF) levels in patients with no active liver disease [alanine amino-
transferase (ALT) ≤50 U/l] (n=44) and active liver disease (ALT > 50 U/l)
(n=40). Thick bars indicate median asTF concentrations, and thin bars the
interquartile range. For illustration purposes, asTF values more than 2000 pg/
ml are shown as 2000 pg/ml.
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Conclusion
Our results showed for the ﬁrst time that asTF plasma
levels were elevated in patients with chronic liver disease.
We found a correlation between plasma asTF and the
degree of hepatic impairment, as assessed by Child–Pugh
score. Importantly, we demonstrated that patients with
HCC who have been treated displayed reduced asTF levels
in comparison with untreated patients and that liver dis-
ease activity, deﬁned as ALT more than 50 U/I, inﬂuences
asTF levels in plasma.
The pathogenic signiﬁcance of our ﬁndings warrants
further investigation.
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